Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2020

View Archived Issues

First COVID-19 patients dosed in phase II study of peginterferon lambda-1a

FDA clears IND application for ZN-d5 for hematologic malignancies

Pancreatic cancer uses autophagy to hide from immune system

Mesoblast initiates phase II/III study of remestemcel-L in patients with COVID-19 ARDS

SIAIS-117, novel ALK degrader as potential therapy for ALK-positive cancer types

Discovery of a novel highly potent and orally active EED inhibitor

Novartis presents preclinical data for TNO-155

Terns patents new THR-beta agonists

Thwarting the hijacker: in vitro study gives "blueprint", drug leads for SARS-CoV-2

Tumor burden reduction seen with Pexa-Vec vaccine in phase I renal cell carcinoma trial

Janssen BioPharma presents new antivirals

Sareum Holdings identifies TYK2 inhibitors

Morphic Therapeutic synthesizes integrin alphavbeta6 antagonists

Medshine Discovery divulges new GLS1 inhibitors

Restoring synaptic transmission for rare neurodevelopmental disease

Neutralizing RSV

Loss-of-function variant in CDC25B causes a syndrome including cardiomyopathy and endocrinopathies

Serum amyloid A may be useful as a marker of COVID-19 severity and prognosis

Preclinical and preliminary phase I results presented for menin/MLL interaction inhibitor SNDX-5613

IPN-60090: a GLS1 inhibitor for the oral treatment of KEAP1/NFE2L2-mutant NSCLC and ASNS-low HGSOC

Phase II trial of nomacopan in bullous pemphigoid meets primary and key secondary efficacy endpoints

Newron discontinues development of sarizotan in Rett syndrome following STARS data

RECCE-327 shows significant antibacterial activity against N. gonorrhoeae bacteria in mice

FDA approves Darzalex Faspro for multiple myeloma

Phase IIb study of STA-363 for disc-related low back pain cleared to begin in Spain